Hospital
University of Wisconsin Hospitals and Clinics Authority
University of Wisconsin Hospitals and Clinics Authority was paid $120.16M by Medicaid between Jan 2018 and Dec 2024, across 963 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 15% of everything it billed.
33Billing provider infoUNIVERSITY OF WISCONSIN HOSPITALS AND CLINICS AUTHORITY
MADISON, WI 53792
MADISON, WI 53792
33aNPI1922043744assigned 06/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$120.16M
24GClaims4,116,346
24DCodes billed963
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#1 of 60
Median peer was paid$2.90M
This provider vs. median41×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 448,732 | $13.48M | |
| 2019 | 478,750 | $15.23M | |
| 2020 | 441,614 | $13.20M | |
| 2021 | 624,384 | $16.77M | |
| 2022 | 653,431 | $16.86M | |
| 2023 | 781,182 | $23.47M | |
| 2024incomplete | 688,253 | $21.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 273,073 | 218,838 | $18.10M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.1% | 84,559 | 66,963 | $7.28M |
| T2023 | Targeted case management; per month | 5.7% | 16,284 | 16,153 | $6.79M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.1% | 42,385 | 29,542 | $4.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.3% | 45,827 | 40,620 | $2.71M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.2% | 42,603 | 37,790 | $2.70M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.2% | 46,442 | 41,408 | $2.65M |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | 2.1% | 1,743 | 1,256 | $2.54M |
| 80053 | Comprehensive metabolic panel | 2.1% | 79,593 | 63,979 | $2.48M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 34,233 | 20,996 | $2.46M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.5% | 34,034 | 29,750 | $1.79M |
| Q3014 | Telehealth originating site facility fee | 1.4% | 44,704 | 37,014 | $1.67M |
951 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 61,317 | $1.58M |
| 99215 | Doctor's office visit, returning patient (complex) | 1.1% | 15,097 | $1.37M |
| 99203 | Doctor's office visit, new patient (routine) | 1.1% | 19,409 | $1.29M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 10,860 | $1.18M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 5,415 | $1.02M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,797 | $1.01M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 10,477 | $1.00M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 14,942 | $986K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 49,094 | $978K |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 1,733 | $975K |
| 77386 | <1% | 7,997 | $970K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 121,685 | $833K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 9,054 | $811K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 102,383 | $790K |
| 64643 | <1% | 5,001 | $777K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,384 | $739K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 18,656 | $735K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,113 | $718K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,692 | $706K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 10,854 | $701K |
| 81001 | <1% | 60,484 | $699K | |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | <1% | 6,223 | $595K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 3,745 | $587K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14,699 | $578K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,661 | $573K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 8,966 | $562K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 6,803 | $547K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 1,349 | $540K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 43,003 | $536K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12,298 | $496K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 9,187 | $486K |
| 76770 | <1% | 5,385 | $472K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 18,836 | $463K |
| 87631 | <1% | 4,906 | $444K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 925 | $429K |
| 64642 | <1% | 3,345 | $427K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,213 | $410K |
| 80061 | Lipid panel | <1% | 16,422 | $397K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15,097 | $372K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,089 | $372K |
| 80197 | <1% | 12,506 | $370K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 22,537 | $366K |
| 96040 | <1% | 2,782 | $348K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,424 | $343K |
| 93321 | <1% | 3,032 | $337K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 880 | $337K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,584 | $330K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 1,013 | $326K |
| 97162 | <1% | 9,656 | $321K | |
| 92567 | <1% | 7,467 | $317K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 8,932 | $310K |
| 96367 | <1% | 4,655 | $310K | |
| 96138 | <1% | 2,256 | $291K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 11,202 | $290K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 4,890 | $281K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,441 | $279K |
| J0475 | Injection, baclofen, 10 mg | <1% | 2,572 | $277K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 8,128 | $277K |
| 93320 | <1% | 2,221 | $271K | |
| G0378 | Hospital observation service, per hour | <1% | 14,491 | $265K |
| 92523 | <1% | 2,825 | $261K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 3,432 | $258K |
| 93308 | <1% | 1,708 | $256K | |
| 82728 | <1% | 15,459 | $255K | |
| 80051 | <1% | 10,415 | $249K | |
| 96139 | <1% | 2,244 | $240K | |
| 82565 | <1% | 24,291 | $232K | |
| 93325 | <1% | 5,585 | $230K | |
| 87081 | <1% | 5,550 | $229K | |
| 96415 | <1% | 2,260 | $228K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 4,088 | $228K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 4,264 | $227K |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 1,885 | $225K |
| 82962 | <1% | 34,931 | $223K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,976 | $223K |
| 74183 | <1% | 2,550 | $223K | |
| 52000 | <1% | 946 | $222K | |
| 84484 | <1% | 34,068 | $221K | |
| 93356 | <1% | 2,329 | $220K | |
| 77336 | <1% | 4,010 | $217K | |
| 82247 | <1% | 14,061 | $214K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,300 | $212K |
| G0175 | Scheduled interdisciplinary team conference (minimum of three exclusive of patient care nursing staff) with patient present | <1% | 4,590 | $211K |
| 87077 | <1% | 14,806 | $204K | |
| 62370 | <1% | 1,551 | $202K | |
| 76497 | <1% | 9,611 | $197K | |
| 20553 | <1% | 2,993 | $196K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,481 | $195K |
| 87070 | <1% | 7,270 | $195K | |
| 84702 | <1% | 11,986 | $194K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,528 | $193K |
| 74230 | <1% | 2,127 | $191K | |
| 81025 | <1% | 18,525 | $191K | |
| 64615 | <1% | 2,850 | $191K | |
| 20610 | <1% | 3,587 | $190K | |
| 85027 | <1% | 34,436 | $189K | |
| 36430 | <1% | 1,867 | $189K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,555 | $188K |
| 83880 | <1% | 8,811 | $184K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,935 | $182K |
| 86832 | <1% | 3,569 | $170K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,693 | $167K |
| 49083 | <1% | 1,013 | $167K | |
| 90837 | Psychotherapy session, about an hour | <1% | 2,912 | $165K |
| 95816 | <1% | 1,411 | $165K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,505 | $164K |
| 92609 | <1% | 3,796 | $162K | |
| 83735 | <1% | 40,382 | $161K | |
| 31575 | <1% | 2,261 | $158K | |
| 95874 | <1% | 3,968 | $158K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 814 | $157K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,425 | $153K |
| 72141 | <1% | 2,435 | $152K | |
| 83970 | <1% | 7,457 | $152K | |
| 96130 | <1% | 1,158 | $151K | |
| 96417 | <1% | 2,956 | $148K | |
| 72197 | <1% | 1,507 | $147K | |
| 49452 | <1% | 730 | $146K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,604 | $146K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,101 | $144K |
| 83605 | <1% | 22,530 | $143K | |
| 86833 | <1% | 3,598 | $141K | |
| 93304 | <1% | 702 | $140K | |
| 84439 | <1% | 9,466 | $139K | |
| 20611 | <1% | 1,385 | $137K | |
| 64644 | <1% | 1,838 | $136K | |
| 86850 | <1% | 16,195 | $133K | |
| 97166 | <1% | 3,882 | $133K | |
| 71250 | <1% | 5,562 | $130K | |
| 87507 | <1% | 404 | $130K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,655 | $129K |
| 70546 | <1% | 1,377 | $127K | |
| 70496 | <1% | 1,678 | $125K | |
| 85610 | <1% | 25,430 | $125K | |
| 97161 | <1% | 4,556 | $124K | |
| 87536 | <1% | 2,238 | $123K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 591 | $122K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,948 | $117K |
| 43235 | <1% | 638 | $115K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,927 | $114K |
| 92579 | <1% | 2,178 | $112K | |
| 52310 | <1% | 465 | $109K | |
| 17250 | <1% | 860 | $109K | |
| 82784 | <1% | 10,211 | $109K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 2,967 | $108K |
| 82803 | <1% | 6,672 | $107K | |
| 82040 | <1% | 6,457 | $106K | |
| 93017 | <1% | 2,863 | $106K | |
| 86780 | <1% | 6,272 | $105K | |
| 70498 | <1% | 1,475 | $104K | |
| 16020 | <1% | 2,048 | $104K | |
| 70491 | <1% | 1,653 | $104K | |
| 83690 | <1% | 25,894 | $104K | |
| 94010 | <1% | 7,960 | $102K | |
| 72158 | <1% | 1,168 | $101K | |
| 77412 | <1% | 888 | $101K | |
| 99205 | Prolong outpt/office vis | <1% | 1,265 | $100K |
| 93296 | <1% | 4,470 | $98K | |
| 92526 | <1% | 2,374 | $97K | |
| 86803 | <1% | 7,978 | $96K | |
| 97116 | <1% | 5,104 | $96K | |
| 86480 | <1% | 2,046 | $95K | |
| 82805 | <1% | 4,191 | $95K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 434 | $95K |
| 87653 | <1% | 1,188 | $94K | |
| 93971 | <1% | 3,649 | $92K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,395 | $92K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,846 | $90K |
| 87102 | <1% | 6,627 | $88K | |
| 92610 | <1% | 1,642 | $88K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,097 | $88K |
| 84466 | <1% | 10,979 | $88K | |
| 95886 | <1% | 1,807 | $85K | |
| 95700 | <1% | 685 | $84K | |
| 95819 | <1% | 791 | $84K | |
| 87497 | <1% | 3,336 | $83K | |
| 87799 | <1% | 5,408 | $83K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,034 | $83K |
| 72156 | <1% | 917 | $81K | |
| 90686 | <1% | 10,055 | $81K | |
| 92611 | <1% | 1,372 | $81K | |
| 82105 | <1% | 3,519 | $81K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,179 | $80K |
| 62369 | <1% | 826 | $80K | |
| 76536 | <1% | 2,017 | $80K | |
| 87641 | <1% | 3,706 | $79K | |
| 83655 | <1% | 2,700 | $78K | |
| 96131 | <1% | 768 | $78K | |
| 97165 | <1% | 2,574 | $77K | |
| 77301 | <1% | 411 | $75K | |
| 87640 | <1% | 2,726 | $75K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,878 | $73K |
| 82607 | <1% | 5,911 | $72K | |
| 29405 | <1% | 754 | $71K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28,766 | $71K |
| 96156 | <1% | 1,220 | $71K | |
| 97113 | <1% | 2,958 | $70K | |
| 29075 | <1% | 969 | $69K | |
| 84450 | <1% | 17,815 | $69K | |
| 80050 | General health panel | <1% | 5,704 | $69K |
| 93975 | <1% | 1,418 | $69K | |
| 43762 | <1% | 1,515 | $68K | |
| 12001 | <1% | 1,063 | $68K | |
| 80069 | <1% | 2,422 | $68K | |
| 82570 | <1% | 15,296 | $68K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,232 | $67K |
| 82077 | <1% | 7,897 | $67K | |
| 77300 | <1% | 1,496 | $67K | |
| 84460 | <1% | 20,647 | $66K | |
| 96136 | <1% | 854 | $66K | |
| 91322 | <1% | 1,031 | $66K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,204 | $64K |
| 96137 | <1% | 811 | $64K | |
| 94060 | <1% | 2,375 | $63K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,790 | $63K |
| 86003 | <1% | 8,868 | $61K | |
| 97163 | <1% | 2,286 | $61K | |
| 76857 | <1% | 3,535 | $60K | |
| 93798 | <1% | 983 | $60K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 58,662 | $60K |
| 92524 | <1% | 1,508 | $59K | |
| 70486 | <1% | 1,623 | $59K | |
| 95716 | <1% | 420 | $58K | |
| 84145 | <1% | 4,211 | $58K | |
| 96101 | <1% | 317 | $57K | |
| 92557 | <1% | 1,899 | $57K | |
| 94660 | <1% | 1,678 | $57K | |
| 80164 | <1% | 1,231 | $56K | |
| 81003 | <1% | 3,061 | $56K | |
| 70544 | <1% | 859 | $56K | |
| 86359 | <1% | 2,172 | $55K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 383 | $55K |
| 64616 | <1% | 476 | $55K | |
| 82310 | <1% | 4,995 | $54K | |
| 51784 | <1% | 1,024 | $54K | |
| 87340 | <1% | 6,873 | $54K | |
| 64400 | <1% | 579 | $54K | |
| 72157 | <1% | 617 | $54K | |
| 82043 | <1% | 4,620 | $54K | |
| 96368 | <1% | 797 | $52K | |
| 83540 | <1% | 11,162 | $52K | |
| 80143 | <1% | 4,399 | $52K | |
| 86140 | <1% | 16,224 | $52K | |
| 86762 | <1% | 1,834 | $52K | |
| 92083 | <1% | 2,517 | $52K | |
| 31622 | <1% | 213 | $52K | |
| 92582 | <1% | 1,622 | $52K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,416 | $51K |
| 76499 | <1% | 1,340 | $51K | |
| 86704 | <1% | 4,404 | $51K | |
| 90670 | <1% | 2,674 | $51K | |
| 76882 | <1% | 1,577 | $51K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,596 | $51K |
| 76642 | <1% | 1,880 | $51K | |
| 77002 | <1% | 2,224 | $51K | |
| 77334 | <1% | 1,272 | $50K | |
| 72146 | <1% | 854 | $49K | |
| 87186 | <1% | 10,252 | $49K | |
| 86360 | <1% | 1,614 | $48K | |
| 86900 | <1% | 15,522 | $48K | |
| 73221 | <1% | 891 | $48K | |
| 82947 | <1% | 12,121 | $48K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,075 | $47K |
| 74018 | <1% | 4,552 | $47K | |
| 95117 | <1% | 1,683 | $47K | |
| 77080 | <1% | 830 | $47K | |
| 84100 | <1% | 16,481 | $46K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 180 | $46K |
| 87015 | <1% | 2,572 | $46K | |
| 86706 | <1% | 5,241 | $46K | |
| 82977 | <1% | 9,212 | $46K | |
| 72082 | <1% | 2,636 | $45K | |
| 92552 | <1% | 1,055 | $44K | |
| 96119 | <1% | 255 | $44K | |
| 92607 | <1% | 769 | $43K | |
| 64450 | <1% | 785 | $43K | |
| 95885 | <1% | 950 | $43K | |
| 11102 | <1% | 522 | $42K | |
| 87506 | <1% | 318 | $42K | |
| 92555 | <1% | 1,147 | $41K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 177 | $41K |
| 72128 | <1% | 1,732 | $41K | |
| 96111 | <1% | 179 | $41K | |
| 86923 | <1% | 3,482 | $41K | |
| 87205 | <1% | 13,619 | $41K | |
| 50200 | <1% | 390 | $40K | |
| 90651 | <1% | 1,394 | $40K | |
| 96152 | <1% | 1,185 | $40K | |
| 92504 | <1% | 2,498 | $40K | |
| 87040 | <1% | 5,645 | $40K | |
| 85379 | <1% | 6,513 | $39K | |
| 80179 | <1% | 4,251 | $39K | |
| 94618 | <1% | 2,362 | $38K | |
| 12011 | <1% | 628 | $38K | |
| 96150 | <1% | 567 | $38K | |
| 82550 | <1% | 5,603 | $38K | |
| 64405 | <1% | 461 | $37K | |
| 29581 | <1% | 353 | $37K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 680 | $37K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 36,310 | $36K |
| 85652 | <1% | 13,978 | $36K | |
| 93976 | <1% | 1,260 | $35K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 31 | $35K |
| 93797 | <1% | 824 | $35K | |
| 96116 | <1% | 259 | $34K | |
| 82950 | <1% | 839 | $34K | |
| 87493 | <1% | 1,125 | $34K | |
| 82533 | <1% | 2,367 | $34K | |
| 82670 | <1% | 902 | $33K | |
| 84075 | <1% | 11,393 | $33K | |
| 84403 | <1% | 1,683 | $33K | |
| 92134 | <1% | 7,581 | $32K | |
| 93225 | <1% | 2,136 | $31K | |
| 82140 | <1% | 2,170 | $31K | |
| 85730 | <1% | 8,434 | $31K | |
| 64447 | <1% | 296 | $31K | |
| 84156 | <1% | 11,087 | $30K | |
| J9299 | Injection, nivolumab, 1 mg | <1% | 33 | $30K |
| 82746 | <1% | 3,536 | $29K | |
| 76870 | <1% | 1,010 | $29K | |
| 86901 | <1% | 15,523 | $29K | |
| 84132 | <1% | 6,595 | $28K | |
| 90677 | <1% | 1,541 | $28K | |
| 90680 | <1% | 1,965 | $28K | |
| 81229 | <1% | 60 | $28K | |
| 51705 | <1% | 922 | $28K | |
| 77338 | <1% | 436 | $28K | |
| 86038 | <1% | 3,073 | $28K | |
| 86235 | <1% | 914 | $28K | |
| 95951 | <1% | 170 | $28K | |
| 86160 | <1% | 3,055 | $28K | |
| 17110 | <1% | 583 | $27K | |
| 90734 | <1% | 1,526 | $27K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,573 | $27K |
| 31579 | <1% | 234 | $27K | |
| 83615 | <1% | 7,100 | $26K | |
| 97167 | <1% | 671 | $26K | |
| 82150 | <1% | 3,251 | $26K | |
| 90911 | <1% | 249 | $26K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,727 | $26K |
| 51741 | <1% | 735 | $24K | |
| 83520 | <1% | 1,301 | $24K | |
| 83021 | <1% | 893 | $24K | |
| 83516 | <1% | 1,835 | $24K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 11,608 | $24K |
| 82330 | <1% | 2,488 | $23K | |
| 85048 | <1% | 3,434 | $23K | |
| G0008 | Administration of influenza virus vaccine | <1% | 5,807 | $23K |
| 94003 | <1% | 92 | $23K | |
| 72131 | <1% | 849 | $22K | |
| 71555 | <1% | 165 | $22K | |
| 84295 | <1% | 1,683 | $21K | |
| 52356 | <1% | 31 | $21K | |
| 87206 | <1% | 6,362 | $20K | |
| 97602 | <1% | 1,454 | $20K | |
| 81000 | <1% | 1,342 | $20K | |
| 84520 | <1% | 10,063 | $20K | |
| 84153 | <1% | 1,560 | $20K | |
| 84481 | <1% | 1,556 | $19K | |
| 76881 | <1% | 663 | $19K | |
| 88307 | <1% | 3,042 | $19K | |
| 64415 | <1% | 113 | $19K | |
| 76942 | <1% | 5,213 | $19K | |
| 93970 | <1% | 513 | $19K | |
| 85018 | <1% | 7,902 | $19K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 248 | $19K |
| 93226 | <1% | 2,137 | $19K | |
| 97597 | <1% | 509 | $19K | |
| 10060 | <1% | 352 | $19K | |
| 87529 | <1% | 444 | $18K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,111 | $18K |
| 92522 | <1% | 400 | $18K | |
| 43760 | <1% | 263 | $18K | |
| 82525 | <1% | 1,078 | $18K | |
| 70543 | <1% | 147 | $18K | |
| 85014 | <1% | 5,960 | $18K | |
| 90716 | <1% | 605 | $18K | |
| 88342 | <1% | 7,039 | $18K | |
| 86708 | <1% | 2,123 | $18K | |
| 72170 | <1% | 4,877 | $17K | |
| 86769 | <1% | 608 | $17K | |
| 81329 | <1% | 160 | $17K | |
| 88341 | <1% | 3,517 | $17K | |
| 85049 | <1% | 1,477 | $17K | |
| 90647 | <1% | 2,276 | $17K | |
| 83993 | <1% | 523 | $16K | |
| 84146 | <1% | 807 | $16K | |
| 96376 | <1% | 15,564 | $16K | |
| 73130 | <1% | 4,340 | $16K | |
| 77066 | Tomosynthesis, mammo | <1% | 886 | $16K |
| 82465 | <1% | 769 | $16K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 158 | $16K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 41 | $15K |
| 84630 | <1% | 1,539 | $15K | |
| 0001A | <1% | 1,561 | $15K | |
| 64483 | <1% | 111 | $15K | |
| 73630 | <1% | 5,385 | $15K | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 13 | $15K |
| 0002A | <1% | 1,401 | $15K | |
| 84550 | <1% | 4,200 | $15K | |
| 76937 | <1% | 1,310 | $15K | |
| 90715 | <1% | 2,829 | $15K | |
| 31624 | <1% | 57 | $15K | |
| 87075 | <1% | 2,766 | $14K | |
| 86356 | <1% | 528 | $14K | |
| 73610 | <1% | 5,087 | $14K | |
| 94726 | <1% | 2,272 | $14K | |
| 86364 | <1% | 1,756 | $14K | |
| 69210 | <1% | 663 | $14K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 118,055 | $14K |
| 86355 | <1% | 557 | $14K | |
| 89051 | <1% | 2,797 | $14K | |
| 83001 | <1% | 733 | $14K | |
| 90480 | <1% | 1,019 | $14K | |
| 73502 | <1% | 3,563 | $14K | |
| 84305 | <1% | 535 | $14K | |
| 74174 | <1% | 198 | $14K | |
| 86592 | <1% | 1,523 | $13K | |
| 96450 | <1% | 104 | $13K | |
| 20552 | <1% | 201 | $13K | |
| 86255 | <1% | 1,330 | $13K | |
| 92133 | <1% | 2,477 | $13K | |
| 95911 | <1% | 324 | $13K | |
| 73090 | <1% | 2,386 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,731 | $12K |
| 73030 | <1% | 4,699 | $12K | |
| 82785 | <1% | 561 | $12K | |
| 90633 | <1% | 1,633 | $12K | |
| 94729 | <1% | 3,497 | $12K | |
| 80175 | <1% | 395 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 31,031 | $12K |
| 77062 | <1% | 503 | $12K | |
| 73560 | <1% | 3,729 | $12K | |
| 20550 | <1% | 159 | $12K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 609 | $12K |
| 92250 | <1% | 3,137 | $12K | |
| 51702 | <1% | 895 | $11K | |
| 97760 | <1% | 813 | $11K | |
| 73110 | <1% | 4,061 | $11K | |
| 97763 | <1% | 683 | $11K | |
| 94799 | <1% | 10,453 | $11K | |
| 96402 | <1% | 533 | $11K | |
| 75561 | <1% | 88 | $11K | |
| 96158 | <1% | 349 | $11K | |
| 93922 | <1% | 570 | $10K | |
| 87517 | <1% | 456 | $10K | |
| 83521 | <1% | 692 | $10K | |
| 85046 | <1% | 2,322 | $10K | |
| 82103 | <1% | 726 | $10K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 225 | $10K |
| 84155 | <1% | 3,981 | $10K | |
| 77295 | <1% | 55 | $10K | |
| 87184 | <1% | 2,203 | $10K | |
| 86225 | <1% | 1,107 | $10K | |
| 73590 | <1% | 3,535 | $10K | |
| 84165 | <1% | 1,889 | $9K | |
| 38222 | <1% | 65 | $9K | |
| 80177 | <1% | 562 | $9K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 578 | $9K |
| 82024 | <1% | 147 | $9K | |
| 87902 | <1% | 52 | $9K | |
| 95930 | <1% | 56 | $9K | |
| 83525 | <1% | 678 | $9K | |
| 92587 | <1% | 360 | $9K | |
| 67311 | <1% | 12 | $9K | |
| 80375 | <1% | 519 | $9K | |
| 80178 | <1% | 339 | $9K | |
| 73700 | <1% | 254 | $9K | |
| 51798 | <1% | 4,121 | $9K | |
| 42830 | <1% | 20 | $9K | |
| 72040 | <1% | 2,245 | $9K | |
| 90656 | <1% | 1,066 | $8K | |
| 72100 | <1% | 2,894 | $8K | |
| 83992 | <1% | 520 | $8K | |
| 90723 | <1% | 2,265 | $8K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 337 | $8K |
| 96132 | <1% | 58 | $8K | |
| 11900 | <1% | 158 | $8K | |
| 94664 | <1% | 930 | $8K | |
| 82378 | <1% | 490 | $8K | |
| 96120 | <1% | 87 | $8K | |
| 36561 | <1% | 26 | $8K | |
| 86334 | <1% | 800 | $8K | |
| 88304 | <1% | 2,503 | $8K | |
| 43249 | <1% | 42 | $8K | |
| 85045 | <1% | 2,743 | $8K | |
| 88185 | <1% | 1,475 | $8K | |
| 73140 | <1% | 2,027 | $8K | |
| 86618 | <1% | 545 | $8K | |
| 84425 | <1% | 588 | $8K | |
| 31231 | <1% | 331 | $7K | |
| 80324 | <1% | 518 | $7K | |
| 86644 | <1% | 744 | $7K | |
| 82248 | <1% | 1,799 | $7K | |
| 92556 | <1% | 584 | $7K | |
| 73552 | <1% | 2,072 | $7K | |
| 88184 | <1% | 1,043 | $7K | |
| 17311 | <1% | 46 | $7K | |
| 82010 | <1% | 955 | $7K | |
| 86787 | <1% | 1,098 | $7K | |
| 82390 | <1% | 731 | $7K | |
| 73080 | <1% | 2,020 | $7K | |
| 76981 | <1% | 421 | $7K | |
| 73564 | <1% | 1,769 | $7K | |
| 96164 | <1% | 159 | $7K | |
| 77065 | Tomosynthesis, mammo | <1% | 540 | $7K |
| 88142 | <1% | 409 | $7K | |
| 77073 | <1% | 979 | $6K | |
| 92608 | <1% | 227 | $6K | |
| 85007 | <1% | 1,500 | $6K | |
| 95910 | <1% | 186 | $6K | |
| 11104 | <1% | 56 | $6K | |
| 83002 | <1% | 414 | $6K | |
| 86765 | <1% | 650 | $6K | |
| 86200 | <1% | 589 | $6K | |
| 75574 | <1% | 73 | $6K | |
| 73562 | <1% | 3,183 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 35,950 | $6K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 82 | $5K |
| 31720 | <1% | 363 | $5K | |
| 88313 | <1% | 3,544 | $5K | |
| 94762 | <1% | 67 | $5K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 177 | $5K |
| 0004A | <1% | 834 | $5K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 74 | $5K |
| 88312 | <1% | 1,636 | $5K | |
| 87625 | <1% | 210 | $5K | |
| 73100 | <1% | 1,245 | $5K | |
| 90620 | <1% | 179 | $5K | |
| 86735 | <1% | 564 | $5K | |
| 86665 | <1% | 414 | $5K | |
| 96416 | <1% | 38 | $5K | |
| 77091 | <1% | 692 | $5K | |
| 81002 | <1% | 269 | $5K | |
| J1611 | Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg | <1% | 172 | $4K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 319 | $4K |
| 12002 | <1% | 74 | $4K | |
| 84255 | <1% | 212 | $4K | |
| 78264 | <1% | 36 | $4K | |
| 99152 | <1% | 5,006 | $4K | |
| 80076 | <1% | 113 | $4K | |
| 90707 | <1% | 817 | $4K | |
| 82610 | <1% | 297 | $4K | |
| 95812 | <1% | 32 | $4K | |
| 88112 | <1% | 1,431 | $4K | |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 25 | $4K |
| 87338 | <1% | 96 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 264 | $4K |
| 73070 | <1% | 1,384 | $4K | |
| 11100 | <1% | 70 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 32,056 | $4K |
| 84446 | <1% | 308 | $3K | |
| 74220 | <1% | 137 | $3K | |
| 77061 | <1% | 126 | $3K | |
| 91200 | <1% | 340 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 36,342 | $3K |
| 51600 | <1% | 89 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 2,793 | $3K |
| 77280 | <1% | 62 | $3K | |
| 94761 | <1% | 6,303 | $3K | |
| 82104 | <1% | 300 | $3K | |
| 0124A | <1% | 262 | $3K | |
| 74240 | <1% | 32 | $3K | |
| 90696 | <1% | 409 | $3K | |
| 90732 | <1% | 707 | $3K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 54 | $3K |
| 90685 | <1% | 102 | $3K | |
| 90714 | <1% | 463 | $3K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 50 | $3K |
| 96153 | <1% | 576 | $3K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 38 | $3K |
| 90381 | <1% | 20 | $3K | |
| 86015 | <1% | 371 | $3K | |
| 97750 | <1% | 259 | $3K | |
| 84590 | <1% | 313 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,679 | $3K |
| 62323 | <1% | 13 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 633 | $2K |
| 0054A | <1% | 237 | $2K | |
| 82951 | <1% | 38 | $2K | |
| 77072 | <1% | 233 | $2K | |
| 77081 | <1% | 343 | $2K | |
| 70487 | <1% | 28 | $2K | |
| 29065 | <1% | 31 | $2K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 15 | $2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 105 | $2K |
| 82945 | <1% | 135 | $2K | |
| 92136 | <1% | 493 | $2K | |
| 83921 | <1% | 153 | $2K | |
| 89050 | <1% | 262 | $2K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 50 | $2K |
| 95974 | <1% | 12 | $2K | |
| 92553 | <1% | 30 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 29,437 | $2K |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 40 | $2K |
| 0071A | <1% | 327 | $2K | |
| 72198 | <1% | 12 | $2K | |
| 86308 | <1% | 350 | $2K | |
| G0249 | Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests | <1% | 214 | $2K |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 69 | $2K |
| 88172 | <1% | 577 | $2K | |
| 84402 | <1% | 102 | $2K | |
| 74019 | <1% | 889 | $2K | |
| 93246 | <1% | 136 | $2K | |
| 86376 | <1% | 205 | $2K | |
| 84207 | <1% | 113 | $2K | |
| 76885 | <1% | 25 | $2K | |
| 82379 | <1% | 108 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 7,579 | $2K |
| 82397 | <1% | 81 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 73 | $2K |
| 85576 | <1% | 141 | $2K | |
| 90700 | <1% | 546 | $2K | |
| 90691 | <1% | 264 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 29,583 | $2K |
| 90710 | <1% | 518 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 46,806 | $2K |
| 88360 | <1% | 497 | $2K | |
| 85246 | <1% | 96 | $2K | |
| 83718 | <1% | 471 | $2K | |
| 85245 | <1% | 94 | $2K | |
| 85520 | <1% | 135 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $2K |
| 73060 | <1% | 699 | $2K | |
| 77085 | <1% | 189 | $2K | |
| 0072A | <1% | 236 | $2K | |
| 92551 | <1% | 55 | $2K | |
| 86304 | <1% | 93 | $2K | |
| 81015 | <1% | 111 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 39 | $2K |
| 51728 | <1% | 39 | $2K | |
| 82627 | <1% | 58 | $2K | |
| 96409 | <1% | 1,058 | $1K | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 30 | $1K |
| 82340 | <1% | 189 | $1K | |
| 86381 | <1% | 141 | $1K | |
| 87634 | <1% | 14 | $1K | |
| 86431 | <1% | 409 | $1K | |
| 80305 | <1% | 49 | $1K | |
| 74420 | <1% | 30 | $1K | |
| 97802 | <1% | 193 | $1K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,052 | $1K |
| 99153 | Mod sedat endo service >5yrs | <1% | 4,344 | $1K |
| 62270 | <1% | 12 | $1K | |
| 80195 | <1% | 41 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 32 | $1K |
| 93298 | <1% | 122 | $1K | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 26 | $1K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,777 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 23,461 | $1K |
| 96401 | <1% | 228 | $1K | |
| 90739 | <1% | 216 | $1K | |
| 70549 | <1% | 12 | $1K | |
| 51726 | <1% | 14 | $1K | |
| 78306 | <1% | 12 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 35,229 | $1K |
| 87071 | <1% | 32 | $1K | |
| 97803 | <1% | 288 | $1K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 59 | $1K |
| 92591 | <1% | 15 | $1K | |
| C1776 | Joint device (implantable) | <1% | 364 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 26,220 | $1K |
| 84134 | <1% | 333 | $993.27 | |
| 99070 | <1% | 113 | $970.73 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 1,353 | $960.72 |
| 82657 | <1% | 15 | $950.19 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,403 | $936.25 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 316 | $935.13 |
| 92652 | <1% | 13 | $926.49 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 15,509 | $922.68 |
| C1769 | Guide wire | <1% | 3,777 | $921.94 |
| 87088 | <1% | 127 | $917.65 | |
| 84681 | <1% | 247 | $906.65 | |
| 76512 | <1% | 44 | $904.72 | |
| 82542 | <1% | 16 | $895.79 | |
| 83090 | <1% | 56 | $866.97 | |
| 85347 | <1% | 380 | $839.82 | |
| 90717 | <1% | 33 | $825.76 | |
| 90694 | <1% | 440 | $811.07 | |
| 84157 | <1% | 198 | $802.60 | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 16 | $799.14 |
| 97810 | <1% | 233 | $779.56 | |
| 80183 | <1% | 25 | $772.98 | |
| 90662 | <1% | 405 | $768.04 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,902 | $763.58 |
| 93299 | <1% | 12 | $750.87 | |
| 36416 | <1% | 1,220 | $746.12 | |
| 80346 | <1% | 519 | $735.09 | |
| 0121A | <1% | 71 | $732.08 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,838 | $728.33 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,597 | $724.84 |
| 83498 | <1% | 29 | $706.50 | |
| 91300 | <1% | 169 | $697.99 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,728 | $678.54 |
| 73600 | <1% | 1,112 | $674.09 | |
| 84300 | <1% | 316 | $667.86 | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 731 | $656.74 |
| 92520 | <1% | 13 | $648.34 | |
| 74455 | <1% | 14 | $647.46 | |
| 95912 | <1% | 12 | $643.79 | |
| 70250 | <1% | 48 | $642.68 | |
| 86036 | <1% | 92 | $640.55 | |
| 97164 | <1% | 13 | $639.91 | |
| 92025 | <1% | 327 | $625.87 | |
| 98960 | <1% | 411 | $624.55 | |
| 17000 | <1% | 28 | $617.47 | |
| 95713 | <1% | 12 | $603.35 | |
| 91321 | <1% | 236 | $602.59 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,891 | $598.82 |
| 82435 | <1% | 261 | $597.73 | |
| 85240 | <1% | 79 | $590.70 | |
| 88173 | <1% | 831 | $589.26 | |
| 86361 | <1% | 38 | $583.23 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,088 | $579.55 |
| 84432 | <1% | 29 | $569.34 | |
| 77090 | <1% | 122 | $561.41 | |
| 84270 | <1% | 28 | $542.66 | |
| 86800 | <1% | 49 | $537.06 | |
| 87449 | <1% | 93 | $528.15 | |
| 83876 | <1% | 40 | $519.75 | |
| 80364 | <1% | 790 | $519.60 | |
| 62368 | <1% | 31 | $514.12 | |
| A9581 | Injection, gadoxetate disodium, 1 ml | <1% | 251 | $497.49 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,591 | $493.74 |
| 84244 | <1% | 25 | $484.92 | |
| 87116 | <1% | 80 | $474.33 | |
| 80326 | <1% | 266 | $454.74 | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 2,809 | $444.48 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 3,787 | $441.76 |
| J1815 | Injection, insulin, per 5 units | <1% | 5,443 | $441.74 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,933 | $441.26 |
| 87385 | <1% | 79 | $422.89 | |
| 88237 | <1% | 14 | $421.64 | |
| 59025 | Fetal non-stress test | <1% | 22 | $419.93 |
| 87427 | <1% | 29 | $418.79 | |
| 86709 | <1% | 47 | $409.51 | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 27 | $403.21 |
| 76825 | <1% | 15 | $402.13 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,406 | $400.53 |
| 84478 | <1% | 35 | $397.95 | |
| 83010 | <1% | 58 | $394.05 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 4,073 | $392.61 |
| 80359 | <1% | 527 | $387.81 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,919 | $385.66 |
| 93280 | <1% | 24 | $385.57 | |
| 80372 | <1% | 520 | $381.20 | |
| 80356 | <1% | 520 | $381.20 | |
| 70355 | <1% | 15 | $379.00 | |
| 80358 | <1% | 520 | $378.57 | |
| 80373 | <1% | 520 | $378.57 | |
| 80353 | <1% | 520 | $377.25 | |
| 80348 | <1% | 520 | $377.25 | |
| 80354 | <1% | 520 | $377.25 | |
| 80360 | <1% | 520 | $377.25 | |
| 80361 | <1% | 520 | $377.25 | |
| 80365 | <1% | 520 | $377.25 | |
| 83883 | <1% | 71 | $368.90 | |
| 86301 | <1% | 38 | $362.37 | |
| 80176 | <1% | 70 | $357.55 | |
| 82239 | <1% | 27 | $353.80 | |
| 85613 | <1% | 42 | $352.25 | |
| 90672 | <1% | 20 | $338.87 | |
| 97035 | <1% | 51 | $328.29 | |
| 93880 | <1% | 14 | $321.66 | |
| 92060 | <1% | 122 | $312.46 | |
| 95991 | <1% | 16 | $291.12 | |
| 96411 | <1% | 613 | $285.92 | |
| 82652 | <1% | 12 | $283.52 | |
| 72070 | <1% | 273 | $277.76 | |
| 86039 | <1% | 35 | $274.22 | |
| 88331 | <1% | 152 | $273.42 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,393 | $271.85 |
| 97032 | <1% | 16 | $270.25 | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 69 | $261.59 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,601 | $261.21 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 22,627 | $258.00 |
| 80347 | <1% | 267 | $256.52 | |
| 82374 | <1% | 91 | $256.24 | |
| 85732 | <1% | 42 | $251.73 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,847 | $248.80 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 988 | $245.47 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 220 | $242.39 |
| 86705 | <1% | 34 | $238.20 | |
| 85250 | <1% | 16 | $236.04 | |
| 97811 | <1% | 190 | $232.18 | |
| 86147 | <1% | 18 | $231.57 | |
| C1729 | Catheter, drainage | <1% | 462 | $226.06 |
| 90653 | <1% | 103 | $220.98 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,519 | $220.12 |
| 76376 | <1% | 683 | $216.65 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 8,732 | $213.68 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,311 | $204.46 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,412 | $196.86 |
| 86357 | <1% | 13 | $195.38 | |
| 0003A | <1% | 20 | $194.96 | |
| 20561 | <1% | 127 | $194.70 | |
| 76827 | <1% | 15 | $191.48 | |
| 0081A | <1% | 24 | $190.80 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 505 | $187.53 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,045 | $186.30 |
| 76391 | <1% | 15 | $185.70 | |
| 51797 | <1% | 42 | $178.82 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,182 | $177.63 |
| 88311 | <1% | 552 | $175.55 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 11,325 | $175.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,935 | $170.29 |
| 97542 | <1% | 13 | $168.46 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,139 | $160.74 |
| 82139 | <1% | 15 | $160.32 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,573 | $156.77 |
| 73000 | <1% | 395 | $146.02 | |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 5,440 | $142.10 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 3,297 | $139.89 |
| 80355 | <1% | 267 | $139.81 | |
| 99188 | <1% | 881 | $137.26 | |
| 82232 | <1% | 28 | $132.21 | |
| 87350 | <1% | 14 | $123.30 | |
| 87176 | <1% | 37 | $122.54 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,499 | $118.67 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,762 | $112.61 |
| 86707 | <1% | 13 | $109.08 | |
| 87106 | <1% | 12 | $106.94 | |
| 36591 | <1% | 64 | $106.11 | |
| 82952 | <1% | 26 | $101.25 | |
| 85384 | <1% | 46 | $101.19 | |
| 92201 | <1% | 277 | $98.10 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 540 | $93.55 |
| 0082A | <1% | 13 | $90.24 | |
| 87045 | <1% | 29 | $87.27 | |
| 92511 | <1% | 37 | $82.60 | |
| 91312 | <1% | 547 | $81.90 | |
| 95970 | <1% | 41 | $81.25 | |
| 99459 | <1% | 32 | $77.36 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,119 | $76.74 |
| 95012 | <1% | 57 | $73.87 | |
| 96165 | <1% | 168 | $71.83 | |
| 82085 | <1% | 12 | $71.09 | |
| 83930 | <1% | 15 | $70.14 | |
| 83935 | <1% | 13 | $65.19 | |
| 87305 | <1% | 16 | $61.90 | |
| 91318 | <1% | 18 | $55.56 | |
| 85660 | <1% | 14 | $51.38 | |
| 86880 | <1% | 24 | $50.13 | |
| 86886 | <1% | 18 | $50.00 | |
| 77293 | <1% | 13 | $47.00 | |
| 51701 | <1% | 13 | $45.52 | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | <1% | 45 | $42.55 |
| 84540 | <1% | 34 | $41.36 | |
| C9399 | Unclassified drugs or biologicals | <1% | 584 | $40.32 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 2,037 | $39.11 |
| 0051A | <1% | 12 | $38.16 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,532 | $35.96 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 994 | $34.25 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 5,727 | $32.89 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,378 | $32.76 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 379 | $32.15 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 20 | $31.90 |
| 87046 | <1% | 31 | $28.39 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,836 | $27.56 |
| 96159 | <1% | 121 | $25.74 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 1,288 | $25.43 |
| 77001 | <1% | 105 | $23.04 | |
| 95250 | <1% | 14 | $22.92 | |
| 90474 | <1% | 516 | $22.40 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 306 | $19.84 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 5,427 | $19.21 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 840 | $18.76 |
| 36592 | <1% | 16 | $18.47 | |
| 96381 | <1% | 31 | $18.15 | |
| 73660 | <1% | 15 | $18.07 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 851 | $16.74 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,627 | $10.51 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 491 | $8.98 |
| G0009 | Administration of pneumococcal vaccine | <1% | 124 | $8.74 |
| A4215 | Needle, sterile, any size, each | <1% | 572 | $8.08 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,465 | $6.32 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 367 | $5.95 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 87 | $4.63 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 190 | $4.23 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 224 | $4.10 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 482 | $3.62 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 427 | $3.06 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 353 | $2.60 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 223 | $2.16 |
| A6211 | Foam dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing | <1% | 31 | $1.78 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 205 | $1.58 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 779 | $1.20 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 36 | $1.15 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 85 | $0.77 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 627 | $0.36 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 235 | $0.28 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 343 | $0.00 |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 0% | 164 | $0.00 |
| 91317 | 0% | 18 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 13 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 61 | $0.00 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 69 | $0.00 |
| 72020 | 0% | 62 | $0.00 | |
| 42975 | 0% | 74 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 210 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 46 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 42 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 43 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 65 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 34 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 44 | $0.00 |
| 72190 | 0% | 13 | $0.00 | |
| C2624 | Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components | 0% | 35 | $0.00 |
| 72080 | 0% | 13 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 81 | $0.00 |
| J9250 | Methotrexate sodium, 5 mg | 0% | 53 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 32 | $0.00 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 0% | 16 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 67 | $0.00 |
| 91315 | 0% | 55 | $0.00 | |
| 94668 | 0% | 27 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 17 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 12 | $0.00 |
| A9300 | Exercise equipment | 0% | 25 | $0.00 |
| 91307 | 0% | 13 | $0.00 | |
| 91305 | 0% | 12 | $0.00 | |
| 90461 | 0% | 235 | $0.00 | |
| 91308 | 0% | 103 | $0.00 | |
| 92202 | 0% | 61 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 26 | $0.00 |
| 99177 | 0% | 728 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 643 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 260 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 392 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 230 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 248 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 706 | $0.00 |
| 95983 | 0% | 15 | $0.00 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 42 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 60 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 33 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 81 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 99 | $0.00 |
| 29105 | 0% | 12 | $0.00 | |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 42 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 59 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 13 | $0.00 |
| 69209 | 0% | 13 | $0.00 | |
| J9999 | Not otherwise classified, antineoplastic drugs | 0% | 64 | $0.00 |
| 77387 | 0% | 92 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 45 | $0.00 |
| A9999 | Miscellaneous dme supply or accessory, not otherwise specified | 0% | 32 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 12 | $0.00 |
| 77089 | 0% | 12 | $0.00 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 16 | $0.00 |
| E1390 | Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKAPLAN, ALAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| University of Wisconsin Hospitals and Clinics Authority | Middleton, WI | $883K |
| University of Wisconsin Hospitals and Clinics Authority | Madison, WI | $27K |
| University of Wisconsin Hospitals and Clinics Authority | Madison, WI | $2K |
| University of Wisconsin Hospitals and Clinics Authority | Madison, WI | $1K |
| University of Wisconsin Hospitals and Clinics Authority | Madison, WI | $1K |
| University of Wisconsin Hospitals and Clinics Authority | Madison, WI | $824.85 |
| University of Wisconsin Hospitals and Clinics Authority | Madison, WI | $348.90 |
| University of Wisconsin Hospitals and Clinics Authority | Madison, WI | $17.88 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.